Wolfe Research Forecasts Strong Price Appreciation for Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company (NYSE:LLY) had its price target increased by equities research analysts at Wolfe Research from $1,050.00 to $1,250.00 in a report released on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the stock. Wolfe Research’s price objective would indicate a potential upside of 23.55% from the stock’s previous close.

Other analysts have also issued research reports about the company. Loop Capital set a $950.00 price target on Eli Lilly and Company in a research note on Monday, November 10th. JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. Guggenheim reaffirmed a “buy” rating and issued a $1,163.00 target price on shares of Eli Lilly and Company in a research report on Wednesday. Sanford C. Bernstein lifted their target price on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research note on Monday, November 24th. Finally, Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,087.32.

Eli Lilly and Company Stock Down 2.1%

NYSE LLY opened at $1,011.74 on Wednesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,111.99. The stock has a market capitalization of $956.48 billion, a PE ratio of 49.50, a PEG ratio of 1.15 and a beta of 0.37. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business’s 50-day moving average is $913.15 and its 200 day moving average is $807.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% on a year-over-year basis. During the same quarter last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brighton Jones LLC raised its stake in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares in the last quarter. Covestor Ltd raised its position in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after purchasing an additional 85 shares during the last quarter. Kaufman Rossin Wealth LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter worth about $242,000. Finally, Plan Group Financial LLC bought a new position in Eli Lilly and Company in the 1st quarter worth about $273,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.